These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17961036)

  • 41. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
    Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
    J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gamma knife radiosurgery for intraventricular meningiomas.
    Kim IY; Kondziolka D; Niranjan A; Flickinger JC; Lunsford LD
    Acta Neurochir (Wien); 2009 May; 151(5):447-52; discussion 452. PubMed ID: 19337685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.
    Youngblood MW; Tran AN; Wang W; An S; Scholtens D; Zhang L; O'Shea K; Pokorny JL; Magill ST; Sachdev S; Lukas RV; Ahmed A; Unruh D; Walshon J; McCortney K; Wang Y; Baran A; Sahm F; Aldape K; Chandler JP; David James C; Heimberger AB; Horbinski C
    Neuro Oncol; 2023 Mar; 25(3):508-519. PubMed ID: 35976058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature.
    Gelerstein E; Berger A; Jonas-Kimchi T; Strauss I; Kanner AA; Blumenthal DT; Gottfried M; Margalit N; Ram Z; Shahar T
    J Clin Neurosci; 2017 Mar; 37():51-53. PubMed ID: 28089420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-resectable slow-growing meningiomas treated by hydroxyurea.
    Loven D; Hardoff R; Sever ZB; Steinmetz AP; Gornish M; Rappaport ZH; Fenig E; Ram Z; Sulkes A
    J Neurooncol; 2004; 67(1-2):221-6. PubMed ID: 15072471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
    Newton HB; Scott SR; Volpi C
    Br J Neurosurg; 2004 Oct; 18(5):495-9. PubMed ID: 15799152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy for meningiomas.
    Kyritsis AP
    J Neurooncol; 1996 Sep; 29(3):269-72. PubMed ID: 8858533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olfactory groove meningioma.
    Adappa ND; Lee JY; Chiu AG; Palmer JN
    Otolaryngol Clin North Am; 2011 Aug; 44(4):965-80, ix. PubMed ID: 21819883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas.
    Ragel BT; Couldwell WT; Wurster RD; Jensen RL
    Neurosurg Focus; 2007; 23(4):E10. PubMed ID: 17961034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic radiation treatment for benign meningiomas.
    Elia AE; Shih HA; Loeffler JS
    Neurosurg Focus; 2007; 23(4):E5. PubMed ID: 17961042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of alkaline phosphatase activity predicts meningioma recurrence.
    Bouvier C; Liprandi A; Colin C; Giorgi R; Quilichini B; Metellus P; Figarella-Branger D
    Am J Clin Pathol; 2005 Aug; 124(2):252-8. PubMed ID: 16040297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Giving another chance to mifepristone in pharmacotherapy for aggressive meningiomas-A likely synergism with hydroxyurea?
    Elmaci İ; Altinoz MA; Sav A; Yazici Z; Ozpinar A
    Curr Probl Cancer; 2016; 40(5-6):229-243. PubMed ID: 27320011
    [No Abstract]   [Full Text] [Related]  

  • 55. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review.
    Scerrati A; Mongardi L; Visani J; Lofrese G; Cavallo MA; Fiorentino A; De Bonis P
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):197-203. PubMed ID: 32116057
    [No Abstract]   [Full Text] [Related]  

  • 56. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas.
    Müller P; Henn W; Niedermayer I; Ketter R; Feiden W; Steudel WI; Zang KD; Steilen-Gimbel H
    Clin Cancer Res; 1999 Nov; 5(11):3569-77. PubMed ID: 10589773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Everolimus effectively blocks pulmonary metastases from meningioma.
    Bertolini F; Pecchi A; Stefani A; Fontana A; Rossi G
    Neuro Oncol; 2015 Sep; 17(9):1301-2. PubMed ID: 26293327
    [No Abstract]   [Full Text] [Related]  

  • 58. Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel.
    Tichomirowa MA; Theodoropoulou M; Daly AF; Yassouridis A; Hansen S; Lu J; Lange M; Goldbrunner RH; Stalla GK; Renner U
    Int J Cancer; 2008 Oct; 123(8):1956-63. PubMed ID: 18688857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxyurea for treatment of meningioma.
    Cusimano MD
    J Neurosurg; 1998 May; 88(5):938-9. PubMed ID: 9576275
    [No Abstract]   [Full Text] [Related]  

  • 60. Hydroxyurea chemotherapy for unresectable or residual meningioma.
    Newton HB; Slivka MA; Stevens C
    J Neurooncol; 2000 Sep; 49(2):165-70. PubMed ID: 11206012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.